1 research outputs found
Indicators of inflammation and proteasis/antiproteasis system and their relation to lung function and clinical caracteristics of patients with chronic obstructive pulmonary disease
Uvod/Cilj: Hronična opstruktivna bolest pluća (HOBP) predstavlja značajan javno zdravstveni problem u celom svetu jer su njena učestalost i posledice u stalnom porastu, naročito u zemljama sa značajnom populacijom pušača. Procene oboljevanja za 2010.godinu su ukazale na 384 miliona slučajeva HOBP uz godišnji mortalitet od 2,9 miliona ljudi [1-3]. Hronična opstruktivna bolest pluća (HOBP) se karakteriše ograničenjem protoka vazduha koje nije potpuno reverzibilno. Ograničenje protoka vazduha je obično progresivno i udruženo sa poremećenim inflamacijskim odgovorom pluća na štetne čestice ili gasove [4,5]. Pacijente obolele od HOBP odlikuje stanje pojačane inflamacije i oksidativnog stresa, pojačane proteolize ekstracelularnog matriksa i neravnoteže u proteaza/antiproteaza sistemu, uz prateće patomorfolološke promene u smislu destrukcije alveola i remodelovanje disajnih puteva. Multikomponentna priroda bolesti podrazumeva pored patoloških promena u disajnom stablu i plućima, i sistemske efekte sa zahvatanjem drugih organskih sistema: kardio-vaskularnog sistema, mišića i kostiju, metabolizma, kognitivnih svojstva i raspoloženja. Cij ovog istraživanja je bio da se ispitaju nivoi pokazatelja sistemske inflamacije i sistema proteaza/antiproteaza i utvrdi njihova povezanost sa pokazateljima plućne funkcije i kliničkim karakteristikama pacijenata sa hroničnom opstruktivnom bolesti pluća. Metod: Ovim istraživanjem su bili obuhvaćeni svi pacijenti sa dijagnozom hronične opstruktivne bolesti pluća koja je postavljena prema GOLD kriterijumima (engl. Global Initiative for Chronic Obstructive Disease - GOLD) [1]) i lečeni su u periodu od maja 2017.godine do januara 2018.godine na Odeljenje za astmu, HOBP i hroničnu respiracijsku insuficijenciju Klinike za pulmologiju KCS. Učestvovalo je ukupno 98 ispitanika, starijih od 40 godina, pušači i bivši pušači, u stabilnoj fazi bolesti, bez drugog respiratornog oboljenja. Kontrolnu grupu je činilo 47 zdravih ispitanika uparenih po polu i godinama. Na pregledu je učinjeno ispitivanje plućne funkcije: spirometrija, difuzijski kapacitet za ugljen-monoksid (CO), telesna pletizmografija...Introduction / Aim: Chronic Obstructive Pulmonary Disease (COPD) is a significant public health issue with a constant increase in disease incidence, especially in countries with a significant population of smokers. Predictions for year 2010 were 384 million cases of COPD with an annual mortality of 2.9 million people [1-3]. Chronic obstructive pulmonary disease (HOBP) is characterized by a limitation of airflow that is not completely reversible. The limitation of airflow is usually progressive and associated with an abnormal inflammatory response to the fumes or gases [4,5]. Patients with COPD are characterized by a state of increased inflammation and oxidative stress, enhanced extracellular matrix degradation and imbalance in the proteasis/antiproteasis system, with accompanying pathomorphologic changes of alveolar destruction and airway remodeling. Multicomponent nature of the disease includes pathological changes in the respiratory tract, as well as systemic effects with the involvement of other organ systems: cardio-vascular system, osteosceletal, metabolism, cognitive properties. The aim of this study was to asses the levels of systemic inflammation and the possible imbalance in protease / antiprotease system and to determine their relation to lung function parameters and clinical characteristics of patients with COPD. Method: This study included all patients diagnosed with COPD according to the Global Initiative for Chronic Obstructive Disease (GOLD) [1], and treated in the period from May 2017 to January 2018 in the Department of Asthma, COPD and chronic respiratory insufficiency in the Clinic for pulmonology, Clinical center of Serbia, Belgrade. Study included 98 subjects, aged 40 and over, smokers and former smokers, in a stable phase of COPD, with no other respiratory disease. Healthy control group included 47 subjects. All subjects completed pulmonary function testing (spirometry, diffusion capacity for carbon monoxide (CO), and body plethysmography), COPD Assessment Test (CAT) and the mMRC dyspnoea scale..